サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1737480

急性間欠性ポルフィリン症の世界市場

Acute Intermittent Porphyria

出版日
ページ情報
英文 367 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
急性間欠性ポルフィリン症の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 367 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

急性間欠性ポルフィリン症の世界市場は2030年までに540万米ドルに達する見込み

2024年に470万米ドルと推定される急性間欠性ポルフィリン症の世界市場は、分析期間2024-2030年にCAGR 2.3%で成長し、2030年には540万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである血液検査は、CAGR 1.8%を記録し、分析期間終了時には230万米ドルに達すると予測されます。尿検査分野の成長率は、分析期間でCAGR 3.4％と推定されます。

米国市場は130万米ドルと推定、中国はCAGR4.4％で成長予測

米国の急性間欠性ポルフィリン症市場は2024年に130万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 4.4%で推移し、2030年には100万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9％と1.7％と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界の急性間欠性ポルフィリン症市場- 主要動向と促進要因のまとめ

急性間欠性ポルフィリン症が希少疾患・希少薬領域で注目を集める理由

急性間欠性ポルフィリン症（AIP）は、ポルホビリノーゲンデアミナーゼという酵素の欠損に起因する希少な遺伝性代謝疾患であり、有毒なポルフィリン前駆体の体内蓄積を引き起こします。生命を脅かす可能性のある神経臓器発作を特徴とするAIPは、通常、激しい腹痛、嘔吐、筋力低下、錯乱、痙攣などの症状を呈します。このような発作は、ホルモンの変動、特定の薬剤、絶食、アルコール、感染症などの要因によって引き起こされることが多いです。この疾患の複雑性、予測不可能性、重症度を考慮すると、早期診断と効果的な疾患管理は極めて重要であるが、世界のほとんどのヘルスケアシステムにおいて、未だ著しく未整備です。

AIPは希少疾患であり、その有病率は人口100万人あたり5～10例と推定されています。しかし、希少疾患に対する認識の高まり、遺伝子スクリーニングプログラムの拡大、診断プロトコルの改善により、AIP症例の認識と報告が増加しています。さらに、医療制度や製薬会社が精密医療におけるアンメットニーズに注目する中、AIPはその明確な分子病態と標的治療の可能性により、注目を集めつつあります。国の希少疾病の枠組みや希少疾病用医薬品の指定にAIPが含まれていることも、市場の関心や研究資金を後押ししています。

治療法と遺伝子研究の進歩は治療経路をどのように形成しているのか？

AIPにおける治療法の革新は、単なる症状の管理ではなく、根本的な生化学的障害に対処する標的治療薬の承認と現在進行中の開発によって促進されています。ヘムアルギネートや凍結乾燥ヘマチンなどのヘミンベースの治療は、急性発作に対する標準治療であり、ヘムプールを補充し、ポルフィリン前駆体の肝生成を抑制します。しかし、静脈内投与、副作用、利用しやすさの問題などの制約から、より患者にやさしい、予防的な選択肢の必要性が浮き彫りになってきました。

大きなブレークスルーは、RNA干渉（RNAi）ベースの治療法の開発です。ジボシランはFDAとEMAに承認されたRNAi薬剤であり、ALAS1（ヘム生合成経路の上流にある律速酵素）の発現を低下させることにより、AIP発作の頻度と重症度を減少させる予防的治療を提供します。その皮下投与と実証された有効性は、AIPの慢性疾患管理における新たな章となりました。遺伝子治療やmRNAベースの技術も、次世代シーケンサーによって個別化された変異に特異的な治療アプローチがより現実的なものになるにつれて、長期的あるいは根治的な治療法として検討されています。

どのような患者ニーズ、診断課題、臨床上の優先事項が、より良い管理ソリューションの需要を牽引しているのか？

最近の進歩にもかかわらず、AIPの現状は診断の遅れ、誤診、断片的な治療経路によって定義されています。過敏性腸症候群、てんかん、精神疾患などの一般的な疾患と症状が重複するため、患者は確定診断を受けるまでに複数回の入院を経験することが多いです。このような診断の遅れは、疾病負担の増加、慢性腎臓病や高血圧などの長期合併症、QOLの低下につながります。AIPをより迅速かつ正確に同定するために、臨床意識の向上、早期の生化学的スクリーニング、救急医療プロトコールへの遺伝子検査の組み込みを求める声が高まっています。

患者の立場からは、利用しやすく、非侵襲的で、予防的な治療法の必要性が重要です。点滴治療のための頻繁な通院、限られた専門医しか利用できないこと、集学的支援の欠如は、AIPの管理を非常に混乱させる可能性があります。このため、自己管理治療、在宅ケアモデル、症状追跡や誘因回避のためのデジタルヘルスツールへの関心が高まっています。健康擁護団体もまた、まれで予測不可能な病気と共存することによる精神衛生への影響について認識を高めており、心理的サポート、患者教育、生活指導を含む治療計画へのより総合的なアプローチを促しています。

地域や治療チャネルを超えた急性間欠性ポルフィリン症市場の成長の原動力は？

急性間欠性ポルフィリン症市場の成長を牽引しているのは、希少疾患治療薬の進歩、希少疾病治療薬の市場開拓に対する世界の関心の高まり、分子診断薬の利用可能性の高まりです。北米、特に米国では、希少疾病用医薬品の指定、迅速承認、財政的優遇措置などによる規制当局の強力な支援が、医薬品イノベーションを促進しています。また、専門治療センターや活発な患者登録の存在も、調査や市場導入を促進しています。欧州では、ドイツ、英国、北欧諸国の医療制度がAIPの治療経路を希少疾患ネットワークに統合し、先進的な治療法や診断法へのアクセスを向上させています。

アジア太平洋地域は、認知度向上キャンペーン、診断インフラ整備、市場拡大の対象地域として徐々に浮上しているが、診断不足が依然として大きな障壁となっています。日本と韓国は、政策支援と希少疾患研究への資金提供の面でリードしています。ラテンアメリカと中東は開発の初期段階にあるが、疾患の認知度向上を目指した医学教育プログラムや共同研究パートナーシップを通じて進展が見られます。

市場セグメンテーションでは、急性治療薬（ヘミン製剤など）と慢性予防治療薬（RNAi治療薬など）の両方が市場を牽引しています。専門薬局、病院の外来診療所、希少疾患センターが主要な流通チャネルです。長期的な治療成績に関する実臨床データが蓄積され、遺伝子標的治療薬のパイプラインが進展するにつれて、AIP治療の展望は、消極的な危機管理から積極的な疾患抑制へと進化すると予想されます。これは、世界的な急性間欠性ポルフィリン症市場にとって転機となるものであり、希少代謝疾患治療薬という広範な領域の中で、急速に成熟するセグメントへと変貌を遂げるものです。

セグメント

診断（血液検査、尿検査、DNA検査、血清検査）、治療（ゴナドトロピン放出ホルモンアナログ製剤、予防的ヘマチン輸液）、最終用途（病院、クリニック、研究センター）

調査対象企業の例（全34件）

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Cardinal Health
  • Dicerna Pharmaceuticals
  • LabCorp
  • Lupin Ltd.
  • Mayo Clinic Laboratories
  • McKesson Corporation
  • Moderna, Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Quest Diagnostics
  • Recordati Rare Diseases
  • Sanofi Genzyme
  • Sun Pharmaceutical Industries Ltd.
  • Swedish Orphan Biovitrum AB（Sobi）

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33413

Global Acute Intermittent Porphyria Market to Reach US$5.4 Million by 2030

The global market for Acute Intermittent Porphyria estimated at US$4.7 Million in the year 2024, is expected to reach US$5.4 Million by 2030, growing at a CAGR of 2.3% over the analysis period 2024-2030. Blood Tests, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$2.3 Million by the end of the analysis period. Growth in the Urine Tests segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Million While China is Forecast to Grow at 4.4% CAGR

The Acute Intermittent Porphyria market in the U.S. is estimated at US$1.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Million by the year 2030 trailing a CAGR of 4.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Acute Intermittent Porphyria Market - Key Trends & Drivers Summarized

Why Is Acute Intermittent Porphyria Attracting Increasing Attention in the Rare Disease and Orphan Drug Space?

Acute Intermittent Porphyria (AIP) is a rare genetic metabolic disorder resulting from a deficiency of the enzyme porphobilinogen deaminase, leading to the accumulation of toxic porphyrin precursors in the body. Characterized by potentially life-threatening neurovisceral attacks, AIP typically presents with symptoms such as severe abdominal pain, vomiting, muscle weakness, confusion, and seizures. These episodic flare-ups are often triggered by factors like hormonal fluctuations, certain medications, fasting, alcohol, and infections. Given the complexity, unpredictability, and severity of the condition, early diagnosis and effective disease management are critical yet remain significantly underdeveloped in most global healthcare systems.

The rarity of AIP, with an estimated symptomatic prevalence of 5 to 10 cases per million population, places it firmly in the domain of orphan diseases. However, growing awareness of rare diseases, expanded genetic screening programs, and improved diagnostic protocols are increasing the recognition and reporting of AIP cases. Moreover, as health systems and pharmaceutical companies focus on unmet needs in precision medicine, AIP is gaining prominence due to its well-defined molecular pathology and potential for targeted therapies. The inclusion of AIP in national rare disease frameworks and orphan drug designations is helping drive market interest and research funding.

How Are Advancements in Treatment Modalities and Genetic Research Reshaping Therapeutic Pathways?

Therapeutic innovation in AIP has been catalyzed by the approval and ongoing development of targeted therapies that address the underlying biochemical disruption rather than just managing symptoms. Hemin-based treatments, such as heme arginate and lyophilized hematin, remain the standard of care for acute attacks, replenishing the heme pool and downregulating the hepatic production of porphyrin precursors. However, limitations including IV administration, side effects, and accessibility issues have highlighted the need for more patient-friendly and preventive options.

A major breakthrough has been the development of RNA interference (RNAi)-based therapies. Givosiran, an FDA- and EMA-approved RNAi drug, offers prophylactic treatment by reducing the expression of ALAS1-the rate-limiting enzyme upstream in the heme biosynthesis pathway-thereby decreasing the frequency and severity of AIP attacks. Its subcutaneous delivery and demonstrated efficacy have marked a new chapter in chronic disease management for AIP. Parallel advancements in gene therapy and mRNA-based technologies are also being explored for long-term or curative interventions, particularly as next-generation sequencing makes personalized and mutation-specific treatment approaches more viable.

What Patient Needs, Diagnostic Challenges, and Clinical Priorities Are Driving Demand for Better Management Solutions?

Despite recent progress, the AIP landscape is still defined by diagnostic delays, misdiagnosis, and fragmented care pathways. Patients often experience multiple hospitalizations before receiving a definitive diagnosis, due to symptom overlap with more common conditions like irritable bowel syndrome, epilepsy, or psychiatric disorders. This diagnostic latency contributes to increased disease burden, long-term complications such as chronic kidney disease or hypertension, and decreased quality of life. There is a growing call for enhanced clinical awareness, early biochemical screening, and integration of genetic testing into emergency care protocols to identify AIP more rapidly and accurately.

From a patient perspective, the need for accessible, non-invasive, and preventive therapies is critical. Frequent hospital visits for IV treatments, limited specialist availability, and a lack of multidisciplinary support can make AIP management highly disruptive. This is driving interest in self-administered treatments, home care models, and digital health tools for symptom tracking and trigger avoidance. Health advocacy organizations are also raising awareness about the mental health impacts of living with a rare and unpredictable illness, prompting a more holistic approach to treatment planning that includes psychological support, patient education, and lifestyle guidance.

What Is Driving the Growth of the Acute Intermittent Porphyria Market Across Geographies and Therapeutic Channels?

The growth in the acute intermittent porphyria market is driven by advancements in rare disease therapeutics, increased global focus on orphan drug development, and the rising availability of molecular diagnostics. In North America, particularly the U.S., strong regulatory support through orphan drug designation, fast-track approvals, and financial incentives is fostering drug innovation. The presence of specialized treatment centers and active patient registries also facilitates research and market adoption. In Europe, national health systems in Germany, the UK, and the Nordics are integrating AIP care pathways into rare disease networks, improving access to advanced therapies and diagnostics.

Asia-Pacific is gradually emerging as a target region for awareness campaigns, diagnostic infrastructure improvement, and market expansion, though underdiagnosis remains a significant barrier. Japan and South Korea are leading in terms of policy support and rare disease research funding. Latin America and the Middle East are in earlier stages of development but are seeing progress through medical education programs and collaborative research partnerships aimed at improving disease visibility.

Segment-wise, the market is driven by both acute management drugs (like hemin products) and chronic prophylactic treatments (such as RNAi therapeutics). Specialty pharmacies, hospital outpatient clinics, and rare disease centers are key distribution channels. As real-world data accumulates around long-term treatment outcomes and as gene-targeted therapies advance through the pipeline, the AIP treatment landscape is expected to evolve from reactive crisis management to proactive disease suppression. This marks a turning point for the global acute intermittent porphyria market-transforming it into a rapidly maturing segment within the broader rare metabolic disorder therapeutics domain.

SCOPE OF STUDY:

The report analyzes the Acute Intermittent Porphyria market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis (Blood Tests, Urine Tests, DNA Tests, Serum Tests); Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions); End-Use (Hospitals, Clinics, Research Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Cardinal Health
  • Dicerna Pharmaceuticals
  • LabCorp
  • Lupin Ltd.
  • Mayo Clinic Laboratories
  • McKesson Corporation
  • Moderna, Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Quest Diagnostics
  • Recordati Rare Diseases
  • Sanofi Genzyme
  • Sun Pharmaceutical Industries Ltd.
  • Swedish Orphan Biovitrum AB (Sobi)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Acute Intermittent Porphyria - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Awareness and Diagnostic Advances Fuel Early Detection of AIP Cases
    • Orphan Drug Designation and Incentives Promote R&D for Targeted Therapies
    • Growth in Genetic Testing Enables Carrier Screening and Family-Based Risk Stratification
    • Emergence of RNA Interference and Gene Therapy Approaches Strengthens the Pipeline
    • Expansion of Specialty Clinics and Rare Disease Networks Improves Patient Access
    • Regulatory Support for Accelerated Approvals Enhances Commercialization Timelines
    • Advances in Prophylactic Therapies Reduce Frequency and Severity of Acute Attacks
    • Increased Collaboration Between Biotech Firms and Academia Spurs Innovation
    • Health Economics Emphasis on Reducing Hospitalizations Strengthens Case for Preventive Drugs
    • Digital Health Tools Support Symptom Monitoring and Crisis Management in AIP Patients
    • Growth in Patient Advocacy Groups Enhances Awareness and Treatment Adherence
    • Expansion of Real-World Evidence Studies Improves Long-Term Outcome Tracking
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Intermittent Porphyria Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acute Intermittent Porphyria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Blood Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Urine Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Urine Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Urine Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for DNA Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for DNA Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for DNA Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Serum Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Serum Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Serum Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gonadotropin-Releasing Hormone Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gonadotropin-Releasing Hormone Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Gonadotropin-Releasing Hormone Analogues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Prophylactic Hematin Infusions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Prophylactic Hematin Infusions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Prophylactic Hematin Infusions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • JAPAN
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • CHINA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • EUROPE
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Acute Intermittent Porphyria by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • FRANCE
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • GERMANY
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Acute Intermittent Porphyria by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • INDIA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Acute Intermittent Porphyria by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Acute Intermittent Porphyria by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Acute Intermittent Porphyria by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030
  • AFRICA
    • Acute Intermittent Porphyria Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Acute Intermittent Porphyria by Diagnosis - Blood Tests, Urine Tests, DNA Tests and Serum Tests Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Acute Intermittent Porphyria by Diagnosis - Percentage Breakdown of Value Sales for Blood Tests, Urine Tests, DNA Tests and Serum Tests for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Acute Intermittent Porphyria by Treatment - Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Acute Intermittent Porphyria by Treatment - Percentage Breakdown of Value Sales for Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Acute Intermittent Porphyria by End-Use - Hospitals, Clinics and Research Centers Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Acute Intermittent Porphyria by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Research Centers for the Years 2015, 2025 & 2030

IV. COMPETITION